InnoCan Pharma Shares Face Sustained Selling Pressure

The equity of InnoCan Pharma continues to experience significant downward momentum. Closing at EUR 4.52 in the previous session, the stock has now broken through several key technical support levels. Trading activity remains subdued, with a modest volume of just 2,178 shares traded on German exchanges, signaling considerable investor caution. This market reassessment reflects concerns over recent financial performance and the implications of the company’s strategic initiatives, including its planned U.S. listing.

Recent fundamental data has been dominated by the company’s nine-month results for the 2025 fiscal period. During the first three quarters, InnoCan Pharma generated revenue of USD 21.6 million. This figure represents a decline of approximately 10% compared to the same Read more...